Ovid Therapeutics Inc. (OVID)Healthcare | Biotechnology | New York, United States | NasdaqCM
2.91 USD
+0.11
(3.929%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.93 +0.02 (0.687%) ⇧ (April 17, 2026, 7:43 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:44 p.m. EDT
OVID is currently in a volatile phase with recent news and price fluctuations. The stock has shown some upward momentum in the last few days, but fundamentals are weak with negative profit margins and a high debt-to-equity ratio. The recent positive phase 1 data and analyst upgrades could provide a short-term boost, but the long-term outlook is uncertain. Investors should consider the high volatility and the lack of dividend yield before making any investment decisions. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.194453 |
| AutoETS | 0.216015 |
| AutoARIMA | 0.216017 |
| AutoTheta | 0.251578 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 47.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.192 |
| Excess Kurtosis | -1.03 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.27 |
| Revenue per Share | 0.098 |
| Market Cap | 439,494,272 |
| Forward P/E | -6.21 |
| Beta | -0.03 |
| Profit Margins | -240.13% |
| Website | https://www.ovidrx.com |
As of April 11, 2026, 2:44 p.m. EDT: The options activity shows a mixed sentiment. Calls and puts are both showing significant activity, with a focus on strikes around $2.50 and $2.00. The ATM IV for calls is relatively high, suggesting some bullish sentiment, while puts have higher IV, indicating caution or bearish expectations. The presence of high OI in out-of-the-money puts suggests some short-term bearishness, but the overall volume and positioning may indicate a potential for a rebound if positive news continues.
| Attribute | Value |
|---|---|
| 52 Week Change | 9.210526 |
| Address1 | Hudson Commons |
| Address2 | 441 9th Avenue 14th Floor |
| All Time High | 15.929 |
| All Time Low | 0.243 |
| Ask | 2.94 |
| Ask Size | 24 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 4,404,590 |
| Average Daily Volume3 Month | 3,047,896 |
| Average Volume | 3,047,896 |
| Average Volume10Days | 4,404,590 |
| Beta | -0.028 |
| Bid | 2.87 |
| Bid Size | 23 |
| Book Value | 1.004 |
| City | New York |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.91 |
| Current Ratio | 8.973 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.93 |
| Day Low | 2.81 |
| Debt To Equity | 10.27 |
| Display Name | Ovid Therapeutics |
| Earnings Timestamp | 1,773,837,000 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -42,166,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.768 |
| Enterprise To Revenue | 45.165 |
| Enterprise Value | 327,539,200 |
| Eps Current Year | -0.41571 |
| Eps Forward | -0.46833 |
| Eps Trailing Twelve Months | -0.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 646 661 4027 |
| Fifty Day Average | 2.059 |
| Fifty Day Average Change | 0.8510001 |
| Fifty Day Average Change Percent | 0.41330746 |
| Fifty Two Week Change Percent | 921.0527 |
| Fifty Two Week High | 3.105 |
| Fifty Two Week High Change | -0.19499993 |
| Fifty Two Week High Change Percent | -0.06280191 |
| Fifty Two Week Low | 0.265 |
| Fifty Two Week Low Change | 2.645 |
| Fifty Two Week Low Change Percent | 9.9811325 |
| Fifty Two Week Range | 0.265 - 3.105 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,991,000,000 |
| Float Shares | 101,219,057 |
| Forward Eps | -0.46833 |
| Forward P E | -6.2135677 |
| Free Cashflow | -25,643,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 7,252,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08522 |
| Held Percent Institutions | 0.41096002 |
| Implied Shares Outstanding | 151,028,956 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. |
| Long Name | Ovid Therapeutics Inc. |
| Market | us_market |
| Market Cap | 439,494,272 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_288870432 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -17,142,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 439,494,259 |
| Number Of Analyst Opinions | 9 |
| Open | 2.849 |
| Operating Cashflow | -38,334,000 |
| Operating Margins | -17.12117 |
| Payout Ratio | 0.0 |
| Phone | 646 661 7661 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.6872845 |
| Post Market Price | 2.93 |
| Post Market Time | 1,776,469,433 |
| Previous Close | 2.8 |
| Price Eps Current Year | -7.0000725 |
| Price Hint | 4 |
| Price To Book | 2.8984065 |
| Price To Sales Trailing12 Months | 60.60318 |
| Profit Margins | -2.40127 |
| Quick Ratio | 8.402 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 3.92858 |
| Regular Market Day High | 2.93 |
| Regular Market Day Low | 2.81 |
| Regular Market Day Range | 2.81 - 2.93 |
| Regular Market Open | 2.849 |
| Regular Market Previous Close | 2.8 |
| Regular Market Price | 2.91 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,376,486 |
| Return On Assets | -0.21822001 |
| Return On Equity | -0.17512 |
| Revenue Growth | 8.447 |
| Revenue Per Share | 0.098 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 151,028,955 |
| Shares Percent Shares Out | 0.0618 |
| Shares Short | 9,337,824 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,090,831 |
| Short Name | Ovid Therapeutics Inc. |
| Short Percent Of Float | 0.067 |
| Short Ratio | 2.0 |
| Source Interval | 15 |
| State | NY |
| Symbol | OVID |
| Target High Price | 7.0 |
| Target Low Price | 3.09 |
| Target Mean Price | 5.01 |
| Target Median Price | 5.0 |
| Total Cash | 69,635,000 |
| Total Cash Per Share | 0.528 |
| Total Debt | 13,419,000 |
| Total Revenue | 7,252,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.472285 |
| Two Hundred Day Average Change | 1.437715 |
| Two Hundred Day Average Change Percent | 0.9765195 |
| Type Disp | Equity |
| Volume | 2,376,486 |
| Website | https://www.ovidrx.com |
| Zip | 10,001 |